Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 11/20 | 0.49 |
| ▸ | GABRB3 | P28472 | 11/20 | 0.49 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.49 |
| ▸ | GABRA2 | P47869 | 5/20 | 0.46 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.46 |
| ▸ | GABRA3 | P34903 | 3/20 | 0.46 |
| ▸ | GABRA6 | Q16445 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | EED | O75530 | 2/20 | 0.45 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.44 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.44 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18511733 | 0.89 | GABRG2 (0.51) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18501504 | 0.87 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18490166 | 0.87 | GABRG2 (0.49) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18490143 | 0.78 | GABRG2 (0.46) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18490304 | 0.74 | SMN1; SMN2 (0.69) | MEN1KMT2AMAPK1HSD17B10LMNA | |
| SCHEMBL18501503 | 0.74 | GABRG2 (0.47) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18490071 | 0.73 | SLC5A1 (0.53) | GABRA2SLC5A1SLC5A2GABRB2ALDH1A1 | |
| SCHEMBL16840766 | 0.71 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18490297 | 0.71 | SLC5A1 (0.48) | GABRG2GABRB3GABRA5GABRA2GABRA1 | |
| SCHEMBL18490179 | 0.70 | SLC5A1 (0.55) | SLC5A1SLC5A2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9920040-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-20 | — | — | US | disclosed |
| US-9920040-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-20 | — | — | US | disclosed |
| US-9908873-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-06 | — | — | US | disclosed |
| US-9908873-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-06 | — | — | US | disclosed |
| US-9856245-B2 | GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-02 | — | — | US | disclosed |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| WO-2017027312-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027309-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027309-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027312-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| WO-2017027310-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| WO-2017027310-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | WO | disclosed |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170044148-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | GABRG2 576/4885GABRB3 570/4885GABRA5 677/4885 |
| US-20170044146-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR52 | GABRG2 294/4885GABRB3 410/4885GABRA5 384/4885 |
| US-20170044147-A1 | GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR55, GPR65 | GABRG2 133/4885GABRB3 98/4885GABRA5 220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.